{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T21:56:27Z","timestamp":1762898187903},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Genetics and Cytogenetics"],"published-print":{"date-parts":[[2006,3]]},"DOI":"10.1016\/j.cancergencyto.2005.08.009","type":"journal-article","created":{"date-parts":[[2006,3,9]],"date-time":"2006-03-09T14:01:05Z","timestamp":1141912865000},"page":"121-134","source":"Crossref","is-referenced-by-count":8,"title":["Isolation of immunoresistant human glioma cell clones after selection with alloreactive cytotoxic T lymphocytes: cytogenetic and molecular cytogenetic characterization"],"prefix":"10.1016","volume":"165","author":[{"given":"German G.","family":"Gomez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marileila","family":"Varella-Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol A.","family":"Kruse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cancergencyto.2005.08.009_bib1","unstructured":"Central Brain Tumor Registry of the United States (CBTRUS). Statistical report: primary brain tumors in the United States, 1995\u20131999. CBTRUS, 2002 [Available at: http:\/\/www.cbtrus.org\/reports\/reports.html]."},{"key":"10.1016\/j.cancergencyto.2005.08.009_bib2","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cancergencyto.2005.08.009_bib3","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3322\/canjclin.48.6.331","article-title":"Primary central nervous system tumors: advances in knowledge and treatment","volume":"48","author":"Prados","year":"1998","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.cancergencyto.2005.08.009_bib4","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3322\/canjclin.43.5.263","article-title":"Brain tumors","volume":"43","author":"Laws","year":"1993","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.cancergencyto.2005.08.009_bib5","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0889-8588(05)70267-7","article-title":"Strategies using the immune system for therapy of brain tumors","volume":"15","author":"Virasch","year":"2001","journal-title":"Hematol Oncol Clin No Am"},{"key":"10.1016\/j.cancergencyto.2005.08.009_bib6","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s11910-001-0024-8","article-title":"Immunologic approaches to therapy for brain tumors","volume":"1","author":"Paul","year":"2001","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.cancergencyto.2005.08.009_bib7","series-title":"Brain tumor immunotherapy","first-page":"149","article-title":"Cytotoxic T-lymphocytes reactive to patient major histocompatibility complex proteins for therapy of brain tumors","author":"Kruse","year":"2001"},{"key":"10.1016\/j.cancergencyto.2005.08.009_bib8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s002620050405","article-title":"Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2","volume":"45","author":"Kruse","year":"1997","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.cancergencyto.2005.08.009_bib9","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/jnci\/88.2.100","article-title":"Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy","volume":"88","author":"Restifo","year":"1996","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.cancergencyto.2005.08.009_bib10","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/00002371-200309000-00001","article-title":"Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma","volume":"26","author":"Rosenberg","year":"2003","journal-title":"J Immunother"},{"key":"10.1016\/j.cancergencyto.2005.08.009_bib11","doi-asserted-by":"crossref","first-page":"4487","DOI":"10.4049\/jimmunol.144.11.4487","article-title":"Immunoselection of a human melanoma resistant to specific lysis by autologous tumor-infiltrating lymphocytes: possible mechanisms for immunotherapeutic failures","volume":"144","author":"Topalian","year":"1990","journal-title":"J Immunol"},{"key":"10.1016\/j.cancergencyto.2005.08.009_bib12","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1006\/gyno.1995.1160","article-title":"Induction of immunocellular resistance to IL-2-activated lymphocytes within ovarian carcinoma cells","volume":"57","author":"Papadopoulos","year":"1995","journal-title":"Gyn Oncol"},{"key":"10.1016\/j.cancergencyto.2005.08.009_bib13","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1002\/ijc.2910430524","article-title":"Generation and partial characterization of melanoma sublines resistant to lymphokine activated killer (LAK) cells: relevance to doxorubicin resistance","volume":"43","author":"Rivoltini","year":"1989","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cancergencyto.2005.08.009_bib14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1006\/scbi.2001.0406","article-title":"Impaired surface antigen presentation in tumors: implications for T cell-based immunotherapy","volume":"12","author":"Ruiz-Cabello","year":"2002","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.cancergencyto.2005.08.009_bib15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/00002371-200301000-00006","article-title":"Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer","volume":"26","author":"Mukherjee","year":"2003","journal-title":"J Immunother"},{"key":"10.1016\/j.cancergencyto.2005.08.009_bib16","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s002620050015","article-title":"Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens","volume":"48","author":"Slingluff","year":"2000","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.cancergencyto.2005.08.009_bib17","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1038\/sj.onc.1205684","article-title":"Matrix metalloproteinase 9 (MMP-9\/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity","volume":"21","author":"Fiore","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.cancergencyto.2005.08.009_bib18","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.4049\/jimmunol.158.10.4521","article-title":"Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back","volume":"158","author":"Walker","year":"1997","journal-title":"J Immunol"},{"key":"10.1016\/j.cancergencyto.2005.08.009_bib19","first-page":"5356","article-title":"Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes","volume":"59","author":"Gastman","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.cancergencyto.2005.08.009_bib20","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/1097-0142(19930715)72:2<491::AID-CNCR2820720227>3.0.CO;2-1","article-title":"Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer","volume":"72","author":"Baxevanis","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.cancergencyto.2005.08.009_bib21","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1073\/pnas.93.7.2909","article-title":"Eradication of established intracranial rat gliomas by transforming growth factor \u03b2 antisense gene therapy","volume":"93","author":"Fakhrai","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cancergencyto.2005.08.009_bib22","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/25387","article-title":"Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer","volume":"396","author":"Pitti","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.cancergencyto.2005.08.009_bib23","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1042\/bj20030659","article-title":"Up-regulation of FLIP in cisplatin-selected HeLa cells causes cross-resistance to CD95\/Fas death signalling","volume":"376","author":"Kamarajan","year":"2003","journal-title":"Biochem J"},{"key":"10.1016\/j.cancergencyto.2005.08.009_bib24","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1084\/jem.190.7.1033","article-title":"Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein","volume":"190","author":"Medema","year":"1999","journal-title":"J Exp Med"},{"key":"10.1016\/j.cancergencyto.2005.08.009_bib25","doi-asserted-by":"crossref","first-page":"11515","DOI":"10.1073\/pnas.201398198","article-title":"Blockade of the granzyme B\/perforin pathway through overexpression of the serine protease inhibitor PI-9\/SPI-6 constitutes a mechanism for immune escape by tumors","volume":"98","author":"Medema","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cancergencyto.2005.08.009_bib26","first-page":"101","article-title":"Isolation and culture of human brain tumor cells","volume":"88","author":"Gomez","year":"2004","journal-title":"Methods Mol Med"},{"key":"10.1016\/j.cancergencyto.2005.08.009_bib27","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0022-1759(80)90280-X","article-title":"A direct comparison of procedures for the detection of mycoplasma in tissue culture","volume":"38","author":"Hessling","year":"1980","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.cancergencyto.2005.08.009_bib28","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/BF02631035","article-title":"Characterization of a continuous human glioma cell line DBTRG-05MG: growth kinetics, karyotype, receptor expression, and tumor suppressor gene analyses","volume":"28A","author":"Kruse","year":"1992","journal-title":"In Vitro Cell Dev Biol"},{"key":"10.1016\/j.cancergencyto.2005.08.009_bib29","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1470-8744.1997.tb00433.x","article-title":"Artificial-capillary-system development of human alloreactive cytotoxic T-lymphocytes that lyse brain tumours","volume":"25","author":"Kruse","year":"1997","journal-title":"Biotechnol Appl Biochem"},{"key":"10.1016\/j.cancergencyto.2005.08.009_bib30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0022-1759(99)00069-1","article-title":"Simultaneous quantitation of 15 cytokines using a multiplexed flow cytometric assay","volume":"227","author":"Carson","year":"1999","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.cancergencyto.2005.08.009_bib31","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1215\/S1152851703000140","article-title":"Interactions of the allogeneic effector leukemic T cell line, TALL-104, with human malignant brain tumors","volume":"6","author":"Gomez","year":"2004","journal-title":"Neuro-Oncol"},{"key":"10.1016\/j.cancergencyto.2005.08.009_bib32","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/pros.10291","article-title":"Spectral karyotype (SKY) analysis of human prostate carcinoma cell lines","volume":"57","author":"van Bokhoven","year":"2003","journal-title":"Prostate"},{"key":"10.1016\/j.cancergencyto.2005.08.009_bib33","article-title":"ISCN 1995: an international system for human cytogenetic nomenclature (1995)","year":"1995"},{"key":"10.1016\/j.cancergencyto.2005.08.009_bib34","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s11626-998-0078-x","article-title":"Receptor expression, cytogenetic, and molecular analysis of six continuous human glioma cell lines","volume":"34","author":"Kruse","year":"1998","journal-title":"In Vitro Cell Dev Biol Anim"},{"key":"10.1016\/j.cancergencyto.2005.08.009_bib35","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0165-4608(97)00364-6","article-title":"Establishment and characterization of a human glioblastoma multiforme cell line","volume":"103","author":"Bakir","year":"1998","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.cancergencyto.2005.08.009_bib36","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/BF02639435","article-title":"Characterization of a new human glioblastoma cell line that expresses mutant p53 and lacks activation of the PDGF pathway","volume":"31","author":"Gjerset","year":"1995","journal-title":"In Vitro Cell Dev Biol Anim"},{"key":"10.1016\/j.cancergencyto.2005.08.009_bib37","first-page":"6683","article-title":"Human glioblastoma cells release interleukin 6 in vivo and in vitro","volume":"50","author":"Van Meir","year":"1990","journal-title":"Cancer Res"},{"key":"10.1016\/j.cancergencyto.2005.08.009_bib38","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1215\/S1152851704001061","article-title":"The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis","volume":"7","author":"Brat","year":"2005","journal-title":"Neuro-oncol"},{"key":"10.1016\/j.cancergencyto.2005.08.009_bib39","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0165-4608(91)90123-C","article-title":"Evolution of tumor chromosome abnormalities after therapy in a pediatric astrocytoma","volume":"53","author":"Sawyer","year":"1991","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.cancergencyto.2005.08.009_bib40","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1023\/A:1005794815663","article-title":"Therapy-related chromosomal changes and cytogenetic heterogeneity in human gliomas","volume":"32","author":"Lai","year":"1997","journal-title":"J Neurooncol"},{"key":"10.1016\/j.cancergencyto.2005.08.009_bib41","article-title":"Cytogenetic and DNA microarray analysis of human glioma cell models resistant to alloreactive cytotoxic T lymphocytes","volume":"46","author":"Gomez","year":"2005","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1016\/j.cancergencyto.2005.08.009_bib42","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/sj.cdd.4401502","article-title":"A highly conserved proapoptotic gene, IKIP, located next to the APAF1 gene locus, is regulated by p53","volume":"11","author":"Hofer-Warbinek","year":"2004","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.cancergencyto.2005.08.009_bib43","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1158\/0008-5472.CAN-03-2932","article-title":"Allelic imbalance of 12q22-23 associated with APAF-1 locus correlates with poor disease outcome in cutaneous melanoma","volume":"64","author":"Fujimoto","year":"2004","journal-title":"Cancer Res"}],"container-title":["Cancer Genetics and Cytogenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165460805004577?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165460805004577?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T07:31:53Z","timestamp":1706945513000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165460805004577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["S0165460805004577"],"URL":"https:\/\/doi.org\/10.1016\/j.cancergencyto.2005.08.009","relation":{},"ISSN":["0165-4608"],"issn-type":[{"value":"0165-4608","type":"print"}],"subject":[],"published":{"date-parts":[[2006,3]]}}}